Navigation Links
ISTA Pharmaceuticals Announces 2010 Financial Guidance
Date:2/9/2010

IRVINE, Calif., Feb. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced financial guidance for the full year 2010.  The Company expects net revenue will be approximately $147 to $165 million.  In addition, ISTA's management anticipates reporting its first profitable year in 2010, with earnings per share for the full year expected to be at least $0.02, excluding any mark-to-market adjustments relating to warrants.  

"2010 will mark ISTA's transition from a young development company to a financially independent commercial organization," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals.  "By offering products with differentiated value propositions for both the physician and the patient and building a strong and motivated commercial team, we will have achieved this milestone five years after launching our first product, Istalol, which was closely followed by the launch of our flagship product, Xibrom.  As we look to 2010 and beyond, Bepreve, Xibrom, XiDay, bepotastine nasal spray, and bromfenac for dry eye stand out as our long-term growth drivers, and we are excited about ISTA's future."  

2010 Financial Outlook in Detail

  • We expect our net revenue for 2010 will be approximately $147 to $165 million.  We continue to assume there will not be a generic competitor to Xibrom in 2010.  We expect sales from our Xibrom franchise (including XiDay, assuming U.S. Food and Drug Administration (FDA) approval) to be in the range of $95 to $105 million<
    '/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
(Date:7/1/2015)... , July 1, 2015 Rock Creek Pharmaceuticals, ... focused on chronic inflammatory disease and neurologic disorders, announced ... study with anatabine citrate, the Company,s lead compound. Results ... of anatabine citrate can significantly inhibit the activation of ... Company is developing this compound in a Phase 1 ...
(Date:7/1/2015)... , July 1, 2015  BioPharmX Corporation (NYSE MKT: ... underwritten public offering of 3,636,364 shares of its common ... per share. BioPharmX has granted the underwriters a 30-day ... common stock at the public offering price. ... an existing stockholder, has agreed to purchase 1,081,081 shares ...
Breaking Medicine Technology:European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 2BioPharmX Corporation Closes Underwritten Public Offering of Common Stock 3
... 12 CVS Caremark Corporation (NYSE: CVS ) today announced ... of approximately 15%, to 8.75 cents per share on the Common ... record on January 22, 2010 . This increase translates into an annual ... per share from the previous rate of 30.5 cents . , ...
... , ST. JOSEPH, Mich. , Jan. 12 ... announced today they have been awarded a $336K Phase I ... for creating a novel type of predictive signatures for drug ... should overcome many shortcomings of existing methods of molecular diagnostics. ...
Cached Medicine Technology:CVS Caremark Corporation Increases Quarterly Dividend 15% 2GeneGo Receives SBIR Grant 2GeneGo Receives SBIR Grant 3
(Date:7/1/2015)... ... July 01, 2015 , ... ... of Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. ... West Virginia on June 26th, the Court rejected the Plaintiff’s assertion that ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... today announced that they will welcome four new members to their industry leading ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... natural forms, such as organically raised chickens and eggs. Eating organic foods and ... chickens is cleaner and more environmentally friendly than production chicken farming. Choosing home ...
(Date:7/1/2015)... York, NY (PRWEB) , ... July 01, 2015 , ... ... $100,000 from the New York Community Trust. The grant will allow CCF to improve ... sharing proven practices. , CCF was formed to respond to many changes in New ...
(Date:7/1/2015)... NY (PRWEB) , ... July 01, 2015 , ... Summer ... taboo with teenagers to fix noses and chins with plastic surgery when they’re looking ... Surgeons (ASPS) more than 236,000 cosmetic procedures were performed on patients ages 19 and ...
Breaking Medicine News(10 mins):Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 2Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 3Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 4Health News:Lymphoma Research Foundation Welcomes New Scientific Advisory Board Members 5Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3
... The Breast, Cancer Patient Protection Act, Championed by ... DeLauro (D-CT) and Moran (R-KS) -, - Effort Part ... Campaign to Encourage Women to Speak Out on Issues That ... a Capitol Hill,press conference, actress Marcia Cross joined Lifetime and ...
... reward center, which can go awry , , WEDNESDAY, Jan. ... specific part of the brain handles what might be ... could lead scientists closer to more effective treatments for ... a brain region is helpful because it provides insight ...
... that field mice have evolved a unique way of ensuring ... infertility in humans. , The team, in collaboration with ... their immunity protection in favour of a more rapid fertilisation ... protein, called CD46. Present in both animals and humans, ...
... week cut death risk in half, study found , , WEDNESDAY, ... of exercise can dramatically prolong a man,s life, new research ... analysis -- the largest such study ever -- found that ... least four to six days a week was enough to ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, ... care today," says Cameron,Truesdell, CEO of LTC Financial Partners, ... shouldn,t be, so we,re going to give,our clients information ... is offering a free guidebook and web links to ...
... Label Highlights CLARITIN Effectively Treats Indoor and ... Schering-Plough,(NYSE: SGP ) today announced ... has,approved additional labeling for CLARITIN(R) (loratadine), which ... relieves,allergy symptoms caused by both indoor (also ...
Cached Medicine News:Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 2Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 3Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 4Health News:Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross and Lifetime Television Deliver 20 Million Online Petition Signatures to Capitol Hill to Urge Congress to Stop 'Drive-Through' Mastectomies 5Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:Evolutionary phenomenon in mice may explain human infertility 2Health News:A Little Regular Exercise Extends Men's Lives 2Health News:A Little Regular Exercise Extends Men's Lives 3Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 2Health News:FDA Approves Labeling Change for Non-Drowsy CLARITIN(R) 3
2.5 mm x 0.6 mm. Overall length: 122 mm, 4.8 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Wide scleral bed. Outside diameter 30.2 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: